Impact of Central Event Adjudication on the PLATO Trial Results
Central adjudication in the PLATO trial was delayed and impacted the primary endpoint by inflating the ticagrelor benefit, resulting in drug approval. The regulatory authorities should consider independent audits when unblinding is suspected in the indication-seeking clinical trials.
Authors
- Victor L. Serebruany (ORCID: https://orcid.org/0000-0002-6597-5445)
- Wendy Ziai (ORCID: https://orcid.org/0000-0003-4548-7353)
- Thomas A. Marciniak (ORCID: https://orcid.org/0000-0003-1801-1624)
- Héctor A. Cabrera-Fuentes (ORCID: https://orcid.org/0000-0002-8502-7098)
- Isabella Hwang
- Brendon Pokov
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- University of Maryland, College Park (US)
- Imam Abdulrahman Bin Faisal University (SA)
- Benito Juárez Autonomous University of Oaxaca (MX)
Publication Details
- Journal
- Reviews in Cardiovascular Medicine
- Published
- 2025-04-27
- DOI
- https://doi.org/10.31083/rcm36733
- Citations
- 2
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.78